Publikationen von Schlegel, Paul-Gerhardt

Corbacioglu, Selim , Lode, Holger, Ellinger, Susanne, Zeman, Florian, Suttorp, Meinolf, Escherich, Gabriele, Bochennek, Konrad, Gruhn, Bernd, Lang, Peter, Rohde, Marius, Debatin, Klaus Michael, Steinbach, Daniel, Beilken, Andreas, Ladenstein, Ruth, Spachtholz, Rainer, Heiss, Peter, Hellwig, Dirk , Tröger, Anja, Koller, Michael , Menhart, Karin , Riemenschneider, Markus J. , Zoubaa, Saida, Kietz, Silke, Jakob, Marcus, Sommer, Gunhild , Heise, Tilman , Hundsdörfer, Patrick, Kühnle, Ingrid, Dilloo, Dagmar, Schönberger, Stefan, Schwabe, Georg, von Luettichau, Irene, Graf, Norbert, Schlegel, Paul-Gerhardt, Frühwald, Michael, Jorch, Norbert, Paulussen, Michael, Schneider, Dominik T., Metzler, Markus, Leipold, Alfred, Nathrath, Michaela, Imschweiler, Thomas, Christiansen, Holger, Schmid, Irene, Crazzolara, Roman, Niktoreh, Naghmeh, Cario, Gunnar, Faber, Joerg, Demmert, Martin, Babor, Florian, Fröhlich, Birgit, Bielack, Stefan, Bernig, Toralf, Greil, Johann, Eggert, Angelika, Simon, Thorsten und Foell, Juergen (2024) Irinotecan and temozolomide in combination with dasatinib and rapamycin versus irinotecan and temozolomide for patients with relapsed or refractory neuroblastoma (RIST-rNB-2011): a multicentre, open-label, randomised, controlled, phase 2 trial. The Lancet Oncology 25 (7), S. 922-932.

Eichinger, Anna , Poetschger, Ulrike, Glogova, Evgenia, Bader, Peter, Basu, Oliver, Beier, Rita, Burkhardt, Birgit, Classen, Carl-Friedrich, Claviez, Alexander , Corbacioglu, Selim , Deubzer, Hedwig E. , Greil, Johann, Gruhn, Bernd, Güngör, Tayfun, Kafa, Kinan, Kühl, Jörn-Sven, Lang, Peter, Lange, Bjoern Soenke, Meisel, Roland, Müller, Ingo, Sauer, Martin G., Schlegel, Paul-Gerhardt, Schulz, Ansgar, Stachel, Daniel, Strahm, Brigitte, Wawer, Angela, Peters, Christina und Albert, Michael H. (2022) Incidence of subsequent malignancies after total body irradiation-based allogeneic HSCT in children with ALL – long-term follow-up from the prospective ALL-SCT 2003 trial. Leukemia 36 (11), S. 2567-2576.